Leaked Data Confirms 42% Melanoma Risk Cut, Triggering Record Moderna Stock Plunge

Key points

• The Phase 3 trial included 1,137 patients with stage IIB-IV melanoma who had undergone surgery, comparing the personalized vaccine plus Keytruda against Keytruda alone.
• After two years, 82% of the vaccine group remained alive without recurrence, compared to 70% in the control group, representing a 42% risk reduction.
• The vaccine, intismeran, targets up to 34 unique mutations in a patient’s tumor, requiring a six-week production process from genetic analysis to delivery.
• Moderna shares fell 18% on the day of the leak, erasing over $17 billion in market value, though the stock remained 200% higher than its August low.
• Regulatory discussions are underway, with full data scheduled for presentation at the European Society for Medical Oncology conference in Madrid.

Background

In August 2026, Moderna and Merck announced that their Phase 3 trial met its primary endpoints, causing Moderna’s stock to surge 177%. This announcement preceded the detailed data release, which was originally scheduled for October 24 at the ESMO conference. Earlier coverage highlighted the potential for mRNA technology to expand beyond melanoma to other cancers, such as pancreatic and lung tumors, though efficacy data for those applications remains pending.

How outlets are covering it

Ars Technica and AP News emphasize the clinical significance of the 42% risk reduction, describing it as a 'defining moment' for personalized cancer therapy. AP highlights expert opinions from MD Anderson and Georgetown University, noting the vaccine’s potential applicability to other cancers. Yahoo Finance focuses on the market reaction, framing the leak as a cause for a record intraday stock drop, noting that the 42% result was lower than the 49% seen in the earlier Phase 2 trial. While all sources agree on the clinical success, they diverge on the primary narrative: medical advancement versus financial volatility.

Why it matters

The results validate the use of mRNA technology for personalized cancer treatment, moving beyond infectious disease applications. The commercial implications are significant, as the high cost and complex manufacturing process of individualized vaccines may impact accessibility. The stock volatility underscores the sensitivity of biotech markets to clinical data timing and magnitude, affecting investor confidence in the sector.

What to watch

Moderna and Merck are engaging with regulatory authorities for approval. Full data will be presented at the ESMO conference in Madrid. Investors will monitor the stock’s recovery and watch for details on lower-risk patient outcomes in the upcoming presentation. The companies are also expanding mRNA vaccine trials to other cancer types, including lung and pancreatic.